A Vascularised Tumouroid-on-A-Chip Model Verifies Synergistic Vasoprotective and Chemotherapeutic Effects

Prolyl hydroxylases (PHD) inhibitors have been observed to normalise blood vessels and increase drug distribution in mice tumour, which increases the effectivity of chemotherapy. However, these effects are yet to be demonstrated in human models. Herein, we developed a vascularised tumouroid-on-a-chip that closely resembles the tumour microenvironment in vivo and demonstrate that the addition of the PHD inhibitor dimethyloxallyl glycine (DMOG) prevents the degradation of normal blood vessels and enhances the efficacy of the chemotherapy drugs paclitaxel and cisplatin in human oesophageal carcinoma tumouroids. Our results suggest that vascularised tumours-on-chips are effective models to evaluate chemotherapeutic drugs under the synergistic effect of a vasoprotective drug.